Guaranteeing the Protection of Confidential Data in Drug Registration Files in Israel
This article was originally published in SRA
Executive Summary
This article describes a new guideline that the Pharmaceutical Administration of Israel’s Ministry of Health has issued on the protection of data in drug registration files. The document, released in December 2008, applies to all employees of the Pharmaceutical Administration and the Institute for the Standardisation and Control of Pharmaceuticals (the institute), as well as to relevant external consultants and advisory committee members. It is particularly noteworthy because it is the first-ever issued guideline in Israel in this respect.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.